Compounding Pharmacy Market

The global compounding pharmacy market is projected to reach USD 21.01 billion by 2031 from USD 15.48 billion in 2026, at a CAGR of 6.3% from 2026 to 2031. Market growth can be attributed to persistent drug shortages in North America and Europe and the continued demand-supply gap for GLP-1 drugs.  

The global compounding pharmacy market is diverse and includes several key players, such as Baxter (US), Empower Pharmacy (US), B. Braun (Germany), and Fagron (Netherlands). Companies in this sector employ various growth strategies to enhance their international presence and strengthen their market positions. For instance, Baxter and Empower Pharmacy focus on developing customized formulations tailored to meet specific patient needs. At the same time, companies like SCA Pharma, QuVa, and B. Braun expand their market presence and capabilities through strategic acquisitions.

To know about the assumptions considered for the study download the pdf brochure

Baxter (US)

Baxter (US) is a leading player in the compounding pharmacy market, offering a broad range of sterile and non-sterile compounding services with a strong presence in developed and emerging markets. The company’s extensive expertise and comprehensive service portfolio have helped it gain a significant market share and establish itself as a dependable partner. Baxter also emphasizes inorganic growth strategies, such as acquisitions and strategic partnerships, to expand its capabilities and global presence.

Empower Pharmacy (US)

Empower Pharmacy (US) is a leading compounding pharmacy specializing in customized medications, including sterile and non-sterile formulations tailored to individual patient needs. The company operates one of the largest and most advanced 503A and 503B compounding facilities in the US, ensuring high-quality, compliant, and scalable production. Empower Pharmacy serves healthcare providers, clinics, and hospitals nationwide, focusing on innovation, regulatory excellence, and patient-centered care. The company continues to grow its capabilities and market presence through infrastructure investments and technology-driven compounding solutions.

B. Braun (Germany)

B. Braun is a global healthcare company with a presence in the compounding pharmacy market through its pharmacy systems, parenteral nutrition solutions, automated compounding technologies, and, historically, Central Admixture Pharmacy Services (CAPS). CAPS has provided compounded sterile preparations and admixture services to hospitals and outpatient facilities in the US, while B. Braun also supplies pharmacy admixture devices and automated systems supporting individualized formulations.

Fagron (Netherlands)

Fagron is a leading global pharmaceutical compounding company specializing in personalized medicines, pharmaceutical raw materials, compounding vehicles, formulations, and sterile and non-sterile compounding services. The company supplies customized medicines to pharmacies, hospitals, and clinics through compounding facilities across the US, Europe, Colombia, Israel, and South Africa, supporting both patient-specific and ready-to-administer preparations. Fagron also maintains a global formulary containing more than 10,000 formulations, including over 3,500 topical formulations and more than 200 sterile-product formulations, strengthening its position in personalized medicine and standardized compounding. The company continues to expand its US compounding presence through acquisitions, including University Compounding Pharmacy, strengthening its nationwide platform spanning both 503A patient-specific and 503B outsourcing services.

Market Ranking

The compounding pharmacy market shows moderate consolidation, with leading companies capturing a significant share through broad portfolios of compounded medications, specialized formulation capabilities, and integrated pharmacy services. Competitive positioning is primarily driven by strengths in patient-specific drug formulation, sterile and non-sterile compounding, customized dosage forms, quality and regulatory compliance, and efficient prescription fulfilment and distribution.

Baxter (US) is a leading provider of compounded sterile preparations (CSPs), including oncology injectables, parenteral nutrition, and specialty formulations. The company utilizes its global hospital network and advanced automation technologies. The company continues to enhance its market position through strategic collaborations and investments to expand its compounding capabilities and ready-to-administer product portfolio.

Empower Pharmacy (US) is among the country’s largest 503A and 503B compounding facilities. It provides customized sterile and non-sterile medications to healthcare providers, hospitals, and patients. Focused on innovation, safety, and compliance, it plays a key role in advancing personalized pharmaceutical care.

B. Braun (Germany) combines compounding expertise with its leadership in infusion therapy and medical devices, providing advanced sterile manufacturing systems and automated parenteral solutions for hospitals worldwide.

Fagron NV (Netherlands) is a global leader in pharmaceutical compounding and personalized medicine, using innovative technologies, software, and automation to support pharmacies and healthcare organizations across major therapeutic areas.

QuVa Pharma (US), an FDA-registered 503B outsourcing facility, focuses on large-scale sterile compounding for hospitals, providing ready-to-administer injectable medications that improve safety and efficiency. Its robust quality systems, nationwide distribution network, and commitment to regulatory excellence make it a trusted outsourcing partner in the US compounding pharmacy market. Regional and independent compounding pharmacies dominate the rest of the market. These companies are gaining ground by focusing on niche areas, building local partnerships, and adopting new compounding technologies in response to rising demand for customized therapies and unique formulations.

Related Reports:

Compounding Pharmacy Market by Product (Oral, Topical, Parenteral), Type (Ingredient Alteration, Dosage Alteration), Therapeutic Application (Pain Management, HRT, Dermatology), Sterility (Sterile), End User, Competition, Region - Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]